Author | Cases n | Controlsa/Cohortb | Source population | Exposure definition | Exposure assessment | Drug | RR | 95% CI |
---|---|---|---|---|---|---|---|---|
Farrow et al. [30] | 612 | 687a | Population based | >1 tablet/week during >6 months. 1 year lag time | Personal Interview | Aspirin (31%) | 0.76 | 0.60–0.97 |
 | 610 |  |  |  |  | NA-NSAIDs (13%) | 0.79 | 0.56–1.10 |
Akre et al. [22] | 480 | 1,055a | Population based | >30 tablets/month. 2 years lag time | Personal Interview | Aspirin (3%) | 0.8 | 0.7–1.1 |
 |  |  |  |  |  | NA-NSAIDs†| 1.1 | 0.6–1.4 |
Zaridze et al. [48] | 448 | 610a | Hospital based | >2 days/week for >6 months | In-hospital Questionnaire | Aspirin (14%) | 0.60 | 0.41–0.90 |
 |  |  |  |  |  | NSAIDs (17%) | 0.65 | 0.45–0.93 |
Langman et al. [36] | 613 | 1,837a | Population based | >7 prescriptions during months 13–36 before index date | Automated Database | NSAIDs (8%) | 0.51 | 0.33–0.79 |
Coogan et al. [26] | 250 | 5,883a | Hospital based | >4 days/week for >3 months. Continuing use during 1 year of lag time | Personal Interview | NSAIDs (7%) | 0.3 | 0.1–0.6 |
Thun et al. [46] | 266 | 635,031b | Cohort | More than 16 times per month for at least one year | Mailed Questionnaire | Aspirin (11%) | 0.53 | 0.34–0.81 |
Schreinemachers et al. [43] | 39 | 12,668b | Cohort | Ever use of aspirin in the 30 days prior to start date | Personal Interview | Aspirin (59%) | 0.93 | 0.49–1.74 |